-
公开(公告)号：US20250144158A1
公开(公告)日：2025-05-08
申请号：US19011691
申请日：2025-01-07
Inventor： Eun Ju PARK , Yun Jung LEE , Hee Soo JEONG , Minn SOHN , Hyeon Tak HAN , So Lim SHIN , Doo-Sang PARK
IPC: A61K35/741 , A23L33/135 , A61P25/00
Abstract: A method according to the present disclosure improves sleep states, maintains a sound sleep, restores the balance of gut microbiota disrupted by sleep disorders, and supports the management of health including metabolic syndrome. Under the provisions of the Budapest Treaty on the International Recognition of the Deposit of Microorganisms for the Purposes of Patent Procedure, the Limosilactobacillus reuteri LM1063 strain was deposited with the international depositary authority: the Korean Collection for Type Cultures on Mar. 23, 2017, under the Accession Number: KCTC 13232BP.
-
公开(公告)号：US20250082620A1
公开(公告)日：2025-03-13
申请号：US18561624
申请日：2023-06-07
Inventor： Byoung-Mog KWON , Dong Cho HAN , Yujin LEE , Jiyeon CHOI , Kyung Chan PARK , Seong-Hwan PARK
IPC: A61K31/4409 , A61K31/165 , A61K45/06 , A61P35/00 , C07C235/80 , C07D213/30
Abstract: The present disclosure relates to novel cinnamamide derivatives and use thereof in preventing or treating cancer.
-
公开(公告)号：US20250064867A1
公开(公告)日：2025-02-27
申请号：US18889046
申请日：2024-09-18
Inventor： Chul-Ho LEE , Byoung-Chan KIM , Yong-Hoon KIM , Jung-Ran NOH , Jae-Hoon KIM , Kyoung-Shim KIM , Dong-Hee CHOI , Young-Keun CHOI , Dong-Ho CHANG , Haiyoung JUNG , Jung Hwan HWANG
IPC: A61K35/741 , A61K35/00 , A61K45/06 , A61P21/00
Abstract: The present invention relates to a method for improving muscle strength, and/or muscle mass by administering a composition containing as an active ingredient at least one selected from the group consisting of Akkermansia muciniphila cells, a culture thereof and a lysate thereof, and a method for preventing or treating muscle diseases where muscle strength and/or mass is weakened by sarcopenia, cachexia or muscle wasting.
-
公开(公告)号：US20240400997A1
公开(公告)日：2024-12-05
申请号：US18270078
申请日：2021-12-28
Inventor： Kyung-Sook CHUNG , Myung Jin SON , Hyun Mi KANG , Ho-Joon LEE , Cho-Rok JUNG , Ok Seon KWON , Seonju MUN
Abstract: The present invention relates to a transformed human hepatic stellate cell line, and a use thereof. The hepatic stellate cell line according to the present invention exhibits an improvement in drug response, and when co-cultured with hepatic stellate cells, does not exhibit a functional decrease in the hepatic cells, and thus can be advantageously used in an in vitro culture model.
-
公开(公告)号：US20240335538A1
公开(公告)日：2024-10-10
申请号：US18290668
申请日：2022-07-21
Inventor： Tae-Don KIM , Sooyun LEE
IPC: A61K39/00 , A61P35/00 , C07K14/705 , C07K14/725 , C07K14/73 , C07K14/735 , C07K16/28 , C07K16/30 , C07K16/32 , C12N5/0783
CPC classification number: A61K39/464404 , A61K39/4611 , A61K39/4613 , A61K39/4614 , A61K39/4615 , A61K39/4631 , A61K39/464406 , A61K39/464411 , A61K39/464419 , A61K39/464429 , A61K39/464466 , A61P35/00 , C07K14/7051 , C07K14/70514 , C07K14/70517 , C07K14/70521 , C07K14/70532 , C07K14/70535 , C07K14/7056 , C07K14/70575 , C07K14/70578 , C07K14/70596 , C07K16/28 , C07K16/2803 , C07K16/2827 , C07K16/2863 , C07K16/2866 , C07K16/303 , C07K16/32 , C12N5/0646 , C07K2317/622 , C07K2319/02 , C07K2319/03 , C12N2510/00
Abstract: The present invention relates to: a novel chimeric antigen receptor containing, as an intracellular signaling domain, an intracellular domain of a receptor containing a dead region; and immune cells expressing the chimeric antigen receptor. In environments in which normal cells are present, the immune cells expressing the chimeric antigen receptor according to the present invention exhibit little or no cytotoxicity and cell death of the immune cells is exhibited, thus ensuring the stability of the normal cells. Conversely, in environments in which target cells are present, the immune cells exhibit more potent cytotoxicity than with conventional techniques utilizing a lone chimeric antigen receptor.
-
Patent Agency Ranking
公开(公告)号：US20240318139A1
公开(公告)日：2024-09-26
申请号：US18599724
申请日：2024-03-08
Inventor： Yee Sook CHO , Han-Seop KIM , Jae Yun KIM , Binna SEOL
IPC: C12N5/0783 , A61K39/00 , A61P35/00 , C07K14/705 , C07K14/725 , C07K16/30 , C12N9/22 , C12N15/11 , C12N15/113 , C12N15/90
CPC classification number: C12N5/0646 , A61K39/4613 , A61K39/4631 , A61K39/464468 , A61P35/00 , C07K14/7051 , C07K14/70517 , C07K16/30 , C12N9/22 , C12N15/11 , C12N15/113 , C12N15/907 , C07K2317/53 , C07K2317/622 , C07K2317/73 , C07K2319/03 , C12N2310/14 , C12N2310/20 , C12N2310/531 , C12N2501/125 , C12N2501/2302 , C12N2501/2307 , C12N2501/2315 , C12N2501/727 , C12N2510/00
Abstract: The present invention relates to a method for preparing directly reprogrammed natural killer (drNK) cells or CAR (chimeric antigen receptor) gene introduced CAR-drNK cells using substances and methods that inhibit BCL11B (B-cell leukemia 11B) gene expression and/or function. The present invention also relates to drNK cells or CAR-drNK cells prepared by a BCL11B gene-based cell reprogramming method, and a cell therapeutic and/or a composition for the prevention or treatment of cancer diseases and infectious diseases caused by viruses, bacteria, fungi, and the like, and/or inflammatory diseases, which contain the cells.
-
公开(公告)号：US12055517B2
公开(公告)日：2024-08-06
申请号：US16759432
申请日：2018-10-29
Inventor： Oh Seok Kwon , Chang Soo Lee , Seon Joo Park , Tai Hwan Ha , Chul Soon Park , Kyung Ho Kim , Jin Yeong Kim
IPC: B32B9/00 , C01B32/186 , C01B32/194 , G01N27/414 , H10K85/20 , H10K85/60 , B82Y30/00
CPC classification number: G01N27/4145 , C01B32/186 , C01B32/194 , G01N27/4146 , H10K85/20 , H10K85/6572 , B82Y30/00 , C01B2204/02 , C01B2204/04 , C01B2204/22 , C01P2002/82 , C01P2002/86 , Y10T428/30
Abstract: The present invention relates to a graphene transistor comprising: a substrate; a graphene channel layer arranged on the substrate; a pair of metals spaced from each other and respectively arranged at opposite ends of the graphene channel layer; and a linker layer arranged on the graphene channel layer and including an N-heterocyclic carbene compound, a fabrication method therefor, and a biosensor comprising the same. The graphene transistor according to the present invention in which the carbene group of the N-heterocyclic carbene compound forms a covalent bond with the graphene channel layer to modify the whole surface of the graphene channel layer exhibits excellent electric conductivity as a transistor and a biosensor comprising the transistor is improved in selectivity and sensitivity.
-
公开(公告)号：US12048296B2
公开(公告)日：2024-07-30
申请号：US16972803
申请日：2019-06-07
Inventor： Yong Sam Kim , Jeong Heon Ko , Nan Ee Lee , Sun Hee Kim
IPC: A01K67/0276 , C07K16/00 , C12N9/22 , C12N15/11 , G01N33/68
CPC classification number: A01K67/0276 , C07K16/00 , C12N9/22 , C12N15/11 , G01N33/68 , A01K2217/075 , A01K2227/105 , A01K2267/01 , C07K2317/41 , C12N2310/20 , C12N2800/80
Abstract: The present disclosure relates to an aglycosylated antibody-producing transgenic mouse and the use of an aglycosylated antibody produced therefrom. When the transgenic mouse of the present disclosure is used, it is possible to easily produce aglycosylated antibodies against various target antigens, and to precisely diagnose disease by detecting a glycoprotein biomarker using the produced aglycosylated antibody.
-
9.发明公开公开(公告)号：US20240238444A1
公开(公告)日：2024-07-18
申请号：US18310969
申请日：2023-05-02
Inventor： Sun Uk KIM , Young Ho PARK , Seung Hwan LEE , Jong Hee LEE , Jae Jin CHA , Han Seop KIM , Un Bin CHAE
CPC classification number: A61K48/0033 , A61K31/7105 , A61K38/465 , A61P39/00 , C12N9/22 , C12N15/11 , C12N2310/20
Abstract: Provided is a composition for the prevention or treatment of Hutchinson-Gilford Progeria syndrome (HGPS) using gene editing, which contains sgRNA that hybridizes to mRNA encoding progerin, which causes HGPS, and a gene encoding Cas13 protein acting on the same. When introduced into the cell of a subject to be treated and only the mRNA encoding progerin is selectively cut. There is no need for co-prescribing with other therapies and fewer side effects occur than traditional farnesyltransferase inhibitors (FTIs). The efficiency is higher than when treated using homologous recombination (HR) at the DNA level, treatment using composition can be made reversibly, and the composition can be applied specifically compared to targeted treatment using RNAi (RNA interference), and has fewer side effects. Compared to treatment using CRISPR/Cas9, which directly acts on DNA and produces irreversible results, treatment using composition is reversible and selectively cut only mRNA encoding progerin, thereby ensuring safety.
-
公开(公告)号：US20240219333A1
公开(公告)日：2024-07-04
申请号：US18003757
申请日：2021-06-15
Applicant: KOREA RESEARCH INSTITUTE OF CHEMICAL TECHNOLOGY , KOREA RESEARCH INSTITUTE OF BIOSCIENCE AND BIOTECHNOLOGY
Inventor： Jung-Hwa Oh , Jaehwan Ahn , Seokjoo Yoon , Hyoung-Yun Han , Mi Young Son , Kwang Bo Jung , Cho Rok Jung , Janghwan Kim
IPC: G01N27/04 , C12M1/26 , C12M1/34 , G01N33/483
CPC classification number: G01N27/041 , C12M33/04 , C12M33/12 , C12M41/40 , G01N33/4833
Abstract: The present invention provides an impedance-based organoid evaluation system comprising an organoid deformation generating unit including a first tube and a plurality of second tubes having a diameter smaller than that of the first tube, connected to one end of the first tube or inserted therein; and an impedance measuring unit connected to the organoid deformation generating unit and including an impedance analyzer for measuring the impedance of the organoid, and evaluating the organoid from the impedance measured by the impedance measuring unit.
-
-
-
-
-
-
-
-
-
Search Results
318
records
(took 0.027 seconds)
